Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/55654
Title: Practice change in the management of metastatic urothelial carcinoma after ASCO 2020.
Authors: 
Keywords: 
Issue Date: 2020
Citation: World J Clin Oncol.2020;(11)12:976-982
Abstract: Metastatic urothelial carcinoma (mUC) is an incurable and aggressive disease. In the past decades there have been few effective treatment options that have impacted the prognosis of mUC patients. However, in the last few years, several drugs have emerged as new treatment choices that are changing the therapeutic landscape of mUC. Immune checkpoint inhibitors (ICIs) and targeted agents are useful treatment strategies that have been incorporated into our clinical practice. Nevertheless, cisplatin-based chemotherapy is still the standard of care in the first-line of metastatic disease. The results of the JAVELIN Bladder 100 phase 3 trial were presented at ASCO 2020, this trial evaluated the role of avelumab, an ICI, as maintenance therapy in patients who had not progressed after first-line platinum-based chemotherapy. The trial met its primary endpoint demonstrating an overall survival benefit with avelumab maintenance. In addition, new drugs and combinations are being evaluated to improve the outcomes of second and subsequent lines. Fibroblast growth factor receptor (FGFR) inhibitors and immunotherapy combinations were some of the strategies presented at ASCO 2020 that have shown promising results. Finally, the development of predictive biomarkers that help us in the decision-making process will be one of the most important challenges in the next years.
PMID: 33437659
URI: https://hdl.handle.net/20.500.12530/55654
Rights: openAccess
ISSN: 2218-4333
Appears in Collections:Fundaciones e Institutos de Investigación > FIIB H. U. Infanta Sofía y H. U. Henares > Artículos

Files in This Item:
File SizeFormat 
PMC7769717.pdf427.19 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons